Huayu Xiaozheng Decoction added to triptorelin and mifepristone for uterine fibroids in 102 women

OBJECTIVE: To expound the efficacy of Huayu Xiaozheng Decoction (HYXZD) combined with triptorelin and mifepristone in the treatment of uterine fibroids, with a particular focus on its effect on uterine artery hemodynamics. METHODS: A total of 102 women with uterine fibroids were enrolled and randomly allocated into a control group and an observation group. The control group received triptorelin plus mifepristone, while the observation group was additionally treated with HYXZD. Both groups were treated for 3 months. Clinical efficacy was compared, and the following parameters were measured before and after treatment: menstrual flow, fibroid volume, sex hormone levels (LH, E, FSH), uterine artery hemodynamics (PI, RI, S/D), hemorheologic parameters (BVH/BVL, PAGT), serum tumor markers (CA125, CEA), adverse reactions, and 1-year recurrence rate. RESULTS: The total effective rate was higher in the observation group relative to the control group (P < 0.05). Before treatment, no notable differences existed between groups in menstrual flow, fibroid volume, LH, E, FSH, PI, RI, S/D, BVH, BVL, PAGT, CA125, or CEA (P > 0.05). Following treatment, both groups showed reductions in menstrual flow, fibroid volume, LH, E, FSH, BVH, BVL, PAGT, CA125, and CEA, with greater reductions in the observation group (P < 0.05); PI, RI, and S/D increased in both groups, with better improvements in the observation group (P < 0.05). The adverse reaction rate was lower in the observation group versus the control group (P = 0.013). At the 1-year follow up, recurrence occurred in 11.76% (6/51) of patients in the control group and 7.84% (4/51) of patients in the observation group (P = 0.505). CONCLUSION: HYXZD combined with triptorelin and mifepristone improves clinical outcomes in uterine fibroid treatment by reducing fibroid size, optimizing hormone levels and hemodynamics, lowering tumor markers, and maintaining safety.